NDA 214103 · Alnylam Pharms INC
Oxlumo
Lumasiran Sodium · Subcutaneous
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Nov 23, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
7
3 Phase 3, 1 recruiting
FAERS reports
386
315 serious, 28 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 1, 2025.
OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . OXLUMO is a HAO1 -directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients. ( 1 )
Mechanism: Lumasiran reduces levels of glycolate oxidase (GO) enzyme by targeting the hydroxyacid oxidase 1 ( HAO1 ) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, a substrate for oxalate production. As the GO enzyme is upstream of the deficient alanine: glyoxylate aminotransferase (AGT) enzyme that causes PH1, the mechanism of action of lumasiran is independent of the underlying AGXT gene mutation. OXLUMO is not expected to be effective in primary hyperoxaluria type 2 (PH2) or type 3 (PH3) because its...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 6, 2022 Supplement 3 · Efficacy OrphanLetterLabel
- Nov 23, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- OXLUMO · LUMASIRAN SODIUM EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lumasiran" as an intervention, any sponsor and status, largest first.
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT02706886 · 52 participants · Start Mar 8, 2016 · Primary completion Jan 23, 2019
Drug: Lumasiran; Placebo · For: Primary Hyperoxaluria Type 1 (PH1)
Sites: Bordeaux, France; Lyon, France; Paris, France · 9 sites in all
- Lumasiran in Hyperoxalaemic Patients on HaemodialysisStatus unknown
Charite University, Berlin, GermanyAcademic, hospital or other
NCT06225544 · 50 participants (planned) · Start Apr 14, 2024 · Primary completion Jan 30, 2025
Drug: Lumasiran; 0.9% Sodium Chloride (placebo) · For: Haemodialysis; Chronic Kidney Disease Requiring Chronic Dialysis; Cardiovascular Disease and 2 more
Sites: Berlin, Germany
- A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03681184 · 39 participants · Start Nov 27, 2018 · Primary completion Nov 5, 2019
Drug: Placebo; Lumasiran · For: Primary Hyperoxaluria Type 1 (PH1)
Sites: San Diego, California; Jacksonville, Florida; Rochester, Minnesota · 17 sites in all
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT04152200 · 21 participants · Start Jan 21, 2020 · Primary completion May 18, 2021
Drug: Lumasiran · For: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria
Sites: Rochester, Minnesota; Houston, Texas; Garran, Australia · 14 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03350451 · 20 participants · Start Apr 4, 2018 · Primary completion Feb 7, 2023
Drug: Lumasiran · For: PH1; Primary Hyperoxaluria; RNAi Therapeutic and 2 more
Sites: Bordeaux, France; Lyon, France; Paris, France · 9 sites in all
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03905694 · 18 participants · Start Apr 22, 2019 · Primary completion Jun 29, 2020
Drug: Lumasiran · For: Primary Hyperoxaluria; Primary Hyperoxaluria Type 1 (PH1)
Sites: Rochester, Minnesota; Houston, Texas; Lyon, France · 9 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT05161936 · 2 participants · Start Jan 27, 2022 · Primary completion Nov 1, 2022
Drug: Lumasiran; Placebo · For: Recurrent Calcium Oxalate Kidney Stone Disease; Elevated Urinary Oxalate Levels
Sites: Birmingham, Alabama; Northridge, California; San Francisco, California · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- renal transplant55
- nephrolithiasis38
- hospitalisation21
- drug ineffective17
- laboratory test abnormal17
- urine oxalate increased17
- acute kidney injury13
- death13
- intentional dose omission13
- liver transplant13
- product dose omission issue13
- dialysis12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 19 |
| 2022 | 33 |
| 2023 | 66 |
| 2024 | 91 |
| 2025 | 121 |
| 2026 | 55 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Oxlumo (Lumasiran Sodium)
2024 spending
$6.4M
Beneficiaries
11
42 claims
Per beneficiary
$578,402
$117,822.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,763,404 |
| 2023 | $0 |
| 2024 | $6,362,423 |
Part B: Oxlumo (Lumasiran Sodium) · HCPCS J0224
2024 spending
$3.7M
Beneficiaries
n/a
44 claims
Per beneficiary
n/a
2024 ASP limit $318.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $2,607,112 |
| 2023 | $3,511,438 |
| 2024 | $3,667,203 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M, Groothoff JW, Shasha-Lavsky H, et al. · Am J Kidney Dis 2023 · Clinical Trial, Phase III
- Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.
Frishberg Y, Saland JM, Lieske JC, et al. · Clin J Am Soc Nephrol 2026 · Clinical Trial, Phase III, Multicenter Study
- Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ, Magen D, Hayes W, et al. · Genet Med 2022 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Long-term lumasiran therapy final results from a Phase 2 open-label extension study in primary hyperoxaluria.
Frishberg Y, Groothoff JW, Hulton SA, et al. · Nephrol Dial Transplant 2026 · Clinical Trial, Phase II, Multicenter Study
- Recent Progression and Treatment Approaches for the Kidney Stone Management.
Sharma K, Nagpal R, Pandey L, et al. · Curr Drug Targets 2025 · Systematic Review
Sponsor: Alnylam Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.